This is a working overview of immunomodulation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
=== Amino acid basic structure === The general structure of the standard amino acids includes a primary amino group, a carboxyl group and the functional group attached to the α-carbon. The different amino acids are identified by the functional group. As a result of the three different groups attached to the α-carbon, amino acids are asymmetrical molecules. For all standard amino acids, except glycine, the α-carbon is a chiral center. In the case of glycine, the α-carbon has two hydrogen atoms, thus adding symmetry to this molecule. With the exception of proline, all of the amino acids found in life have the L-isoform conformation. Proline has a functional group on the α-carbon that forms a ring with the amino group.
The weathering of limestone, now exposed at the land surface, produces the lime-rich soils that are so prevalent in the fertile farmland of the Valley and Ridge province. During this continental break-up, around 600 million to 560 million years ago, volcanic activity was present along the tectonic margins. There is evidence of this activity in today's Blue Ridge Mountains. Mount Rogers, Whitetop Mountain, and Pine Mountain are all the result of volcanic activity that occurred around this time. Evidence of subsurface activity, dikes and sills intruding into the overlying rock, is present in the Blue Ridge as well. For instance, mafic rocks have been found along the Fries Fault in the central Blue Ridge area of Montgomery County, Virginia. One of the best examples of mafic rocks from the breakup of Rodinia is the Catoctin Formation. Erupted during the final stages of rifting associated with Rodinia (570–550 Ma), these rocks where later metamorphosed into Greenstone.
== Innovation == The Global Innovation Index 2024, by World Intellectual Property Organization: Thailand ranked 41 of 133 nations. The Global Innovation Index 2019 ranked Thailand 43 of 129 nations. Other ASEAN nations ranked were: Singapore, 8; Malaysia, 35; Vietnam, 42; Philippines, 54; Brunei, 71; Indonesia, 85; Cambodia, 98. The Bloomberg Innovation Index, 2018 ranked Thailand 45 of 50 nations (1=most innovative; 50=less innovative). Singapore was ranked 3 and Malaysia number 26. The Bloomberg Innovation Index, 2017 ranked Thailand 44 of 50 nations (1=most innovative; 50=less innovative), a rise from 47 in the 2016 ranking. Other ASEAN nations ranked were Singapore, 6 of 50 and Malaysia, 23 of 50. The Global Innovation Index 2015 ranked Thailand 55 of 141 (1=best; 141=worst) countries.
Sources: en.wikipedia.org
The combine genetic phylogenetic and structural analysis concluded that the original type-3 copper protein possessed a single peptide and grouped into α subclass. The ancestral protein gene underwent to two duplication i.e., first one prior to divergence of unknown eukaryotic lineage and second one before diversification. The prior duplication gave rise to cytosolic form(β) and latter duplication gave membrane bound form (Γ). The structural comparison concluded that active site of α and γ forms are covered by aliphatic amino acids and β form covered with aromatic residue. Thus, the evolution of these gene family is the lineage of multicellular eukaryotes due to loss of one or more of these three subclasses and lineage-specific expansion of one or both of the remaining subclasses. The genomic conserved nucleotide alignments of the tyrosinase among the vertebrate family like frogs, snakes and human suggests that it has evolved from one ancestral tyrosinase gene. The duplication and mutation of this gene is probably responsible for the emergence of a tyrosinase-related gene.
As he neared death after suffering strokes, Lenin's Testament of December 1922 named Trotsky and Stalin as the most able men in the Central Committee, but he harshly criticised them. Lenin said that Stalin should be removed from being the General Secretary of the party and that he be replaced with "some other person who is superior to Stalin only in one respect, namely, in being more tolerant, more loyal, more polite, and more attentive to comrades." Upon his death on 21 January 1924, Lenin's political testament was read aloud to the Central Committee, who chose to ignore Lenin's ordered removal of Stalin as General Secretary because enough members believed Stalin had been politically rehabilitated in 1923. Consequent to personally spiteful disputes about the praxis of Leninism, the October Revolution veterans Lev Kamenev and Grigory Zinoviev said that the true threat to the ideological integrity of the party was Trotsky, who was a personally charismatic political leader as well as the commanding officer of the Red Army in the Russian Civil War and revolutionary partner of Lenin. To thwart Trotsky's likely election to head the party, Stalin, Kamenev and Zinoviev formed a troika that featured Stalin as General Secretary, the de facto centre of power in the party and the country. The direction of the party was decided in confrontations of politics and personality between Stalin's troika and Trotsky over which Marxist policy to pursue, either Trotsky's policy of permanent revolution or Stalin's policy of socialism in one country.
== Risk factors == Hospitals are primary transmission sites for CRE-based infections. Up to 75% of hospital admissions attributed to CRE were from long-term care facilities or transferred from another hospital. Suboptimal maintenance practices are the largest cause of CRE transmission. This includes the failure to adequately clean and disinfect medication cabinets, other surfaces in patient rooms, and portable medical equipment, such as X-ray and ultrasound machines that are used for both CRE and non-CRE patients. Thus far, CRE have primarily been nosocomial infectious agents. Almost all CRE infections occur in people receiving significant medical care in hospitals, long-term acute care facilities, or nursing homes. Independent risk factors for CRE infection include use of beta-lactam antibiotics and the use of mechanical ventilation. Patients with diabetes have also been shown to be at an elevated risk for acquiring CRE infections. When compared to other hospitalized patients, those admitted from long-term acute care (LTAC) facilities have significantly higher incidence of colonization and infection rates. Another 2012 multicenter study found that over 30% of patients with recent exposure to LTAC were colonized or infected with CRE. A person susceptible to CRE transmission is more likely to be female, have a greater number of parenteral nutrition-days (days when the person received nutrition via the bloodstream), and to have had a significant number of days breathing through a ventilator.
Sources: en.wikipedia.org
== Director of the Center for Medicare (2025–present) == In November 2024, Adam Boehler recommended to Donald Trump that he hire Klomp. In January 2025, The Washington Post reported that Klomp would serve as the director of the center for Medicare. He was sworn in on April 21. As the center's director, Klomp sought aggressive cost-saving measures. He privately met with Stephen J. Hemsley, the chief executive of UnitedHealth Group, to discuss billing policies and supplemental benefits related to Medicare, and negotiated with Albert Bourla, the chief executive of Pfizer, to discuss drug prices for TrumpRx. Klomp told The Wall Street Journal in January 2026 that the Center for Medicare would focus on improving payment accuracy, giving insurers stable reimbursement, and ensuring Medicare Advantage's stability. He criticized the risk-adjustment system, stating that it overvalued large insurers. Within the Trump administration, Klomp "quickly developed a reputation as a behind-the-scenes fixer", according to The Washington Post. His negotiations with medical companies earned Trump's praise. In February 2026, secretary of health and human services Robert F. Kennedy Jr. appointed Klomp to oversee operations at the Department of Health and Human Services as its chief counselor. The move was promoted by Susie Wiles, the White House chief of staff. Klomp's position involved directing health agencies and aligning their messages with the Trump administration's priorities. He delayed a vaccine announcement out of political concerns.
Its two substrates are xylitol and the oxidised cofactor nicotinamide adenine dinucleotide phosphate (NADP+). The products are L-xylulose, reduced NADPH, and a proton. This enzyme belongs to the superfamily of short-chain oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is xylitol:NADP+ 2-oxidoreductase (L-xylulose-forming).
=== Pharmacodynamics === Several components of the signaling cascade that mediates the HMB-induced increase in human skeletal muscle protein synthesis have been identified in vivo. Similar to HMB's metabolic precursor, L-leucine, HMB has been shown to increase protein synthesis in human skeletal muscle via phosphorylation of the mechanistic target of rapamycin (mTOR) and subsequent activation of mTORC1Tooltip mechanistic target of rapamycin complex 1, which leads to protein biosynthesis in cellular ribosomes via phosphorylation of mTORC1's immediate targets (i.e., the p70S6 kinase and the translation repressor protein 4EBP1). Supplementation with HMB in several non-human animal species has been shown to increase the serum concentration of growth hormone and insulin-like growth factor 1 (IGF-1) via an unknown mechanism, in turn promoting protein synthesis through increased mTOR phosphorylation. Based upon limited clinical evidence in humans, supplemental HMB appears to increase the secretion of growth hormone and IGF-1 in response to resistance exercise. As of 2016, the signaling cascade that mediates the HMB-induced reduction in muscle protein breakdown has not been identified in living humans, although it is well-established that it attenuates proteolysis in humans in vivo. Unlike L-leucine, HMB attenuates muscle protein breakdown in an insulin-independent manner in humans.
Hosokawa Micron Powder Systems is an American company located in Summit, New Jersey, which designs and manufactures equipment for size reduction, classification and mixing of chemical, pharmaceutical and food materials. The company was started in 1923 by Louis Ruprecht named Pulverizing Company and was later bought by the Hosokawa Micron Group in 1985.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.